Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (317)	1/28/2005 1:11:17 PM
From: Jim Oravetz	Read Replies (1) of 370

Vion Pharma Gets Cure Period To Comply With Nasdaq Rule DOW JONES NEWSWIRES January 28, 2005 7:52 a.m. WASHINGTON -- Vion Pharmaceuticals Inc. (VION) disclosed Friday that it was provided a "cure period" to regain compliance with Nasdaq's audit committee composition requirements. The biopharmaceutical company said in a document filed with the Securities and Exchange Commission that it told Nasdaq on Thursday that it wasn't in compliance with the rule because of a vacancy on the audit committee that resulted from the previously announced death of Walter B. Wriston. Vion has until its annual shareholders' meeting or Jan. 19, 2006, to regain compliance with the audit committee requirements. In the meantime, the company will be included in a list of non-compliant Nasdaq companies on Nasdaq's Web site on or after Feb. 3, the filing said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next